Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2005-04-12
2005-04-12
Fredman, Jeffrey (Department: 1637)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091200, C536S023100, C536S024300
Reexamination Certificate
active
06878518
ABSTRACT:
The invention provides a diagnostics assay for measuring the responsiveness to a drug by comparing the mRNA levels of a gene that responds to the drug, such as a steroid, to the mRNA levels of a gene that does not respond to the drug. Methods according to the invention are useful for predicting the ability of a patient (or a tissue, body fluid or cell sample in vitro) to respond to a drug or steroid at any stage of their treatment (i.e., before, during or after), and to monitor the patient (or a tissue, body fluid or cell) over time to assess continued responsiveness to the drug or steroid.
REFERENCES:
patent: 5744304 (1998-04-01), Munford
patent: 5851822 (1998-12-01), Munford
patent: 6300085 (2001-10-01), Alkon
Chikanza et al, “The effects of hydrocortisone on in vitro lymphocyte proliferation and interleukin 2 and 4 production in corticosteroid sensitive and resistant subjects” (Eur. J. Clinical Investigation (1993) 23:845-850).*
Yap et al, “Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: Evidence for increased IL-13 mRNA expression in relapse” (J. Am. Soc. Nephrol. (1999) 10:529-537).*
Baumann et al., “Interaction of Cytokine- and Glucocorticoid-Response Elements of Acute-Phase Plasma Protein Genes”, The Journal of Biological Chemistry, vol. 265, No. 36, pp. 22275-22281, Dec. 25, 1990.
Nickerson et al., “Automated DNA Diagnostics Using an ELISA-Based Oligonucleotide Ligation Assay”, Proc. Natl. Acad. Sci., vol. 87, pp. 8923-8927, Nov. 1990.
Scheidereit et al., “The glucocorticoid Receptor Binds to Defined Nucleotide Sequences Near the Promoter of Mouse Mammary Tumour Virus”, Nature, vol. 304, pp. 749-752, Aug. 25, 1983.
Tobe et al., “Single-Well Genotyping of Dialletic Sequence Variations by a Two-Color ELISA-Based Oligonucleotide Ligation Assay”, Nucleic Acids Research, vol. 24, No. 19, 1996.
Butler et al., “Structure of the Mouse Serum Amyloid A 5 (SAA5) Gene: Relationship to Other Members of the Serum Amyloid A Family”, Scand. J. Immunol., vol. 45, pp. 160-165, 1997.
Butler et al., “Mapping of the Mouse Serum Amyloid A Gene Cluster by Long-Range Polymerase Chain Reaction”, Immunogenetics, vol. 44, pp. 468-474, 1996.
Cohen et al., “Therapy of Relapsing Multiple Sclerosis. Treatment Approaches for Nonresponders”, J. Neuroimmunol., vol. 98, pp. 29-36, 1999.
Cunnane et al., “Amyloid Precursors and Amyloidosis in Rheumatoid Arthritis”, Bailliére's Clinical Rheumatol., vol. 13, No. 4, pp. 615-628, 1999.
Cunnane et al., “Serum Amyloid A in the Assessment of Early Inflammatory Arthritis”, Rheumatol., 27:1, 2000.
Gaughan et al., “Ribozyme Mediated Cleavage of Acute Phase Serum Amyloid A (A-SAA) mRNA in Vitro”, FEBS Letters, 374, pp. 241-245, 1995.
Gaughan et al., “Efficient In Vitro Cleavage of Mouse Acute Phase Serum Amyloid A mRNA Mediated by a Synthetic Hammerhead Ribozyme”, Scand. J. Immunol., vol. 46, pp. 51-58, 1997.
Grehan et al., “Expression of a Biologically Active Recombinant Mouse IL-1 Receptor Antagonist and its Use in Vivo to Moduate Aspects of the Acute Phase Response”, J. Immunol., pp. 369-378, 1997.
Grehan et al., “Down-Regulation of the Major Circulating Precursors of Proteins Deposited in Secondary Amyloidosis by a Recombinant Mouse Interleukin-1 Receptor Antagonist”, Eur. J. Immunol., vol. 27, pp. 2593-2599, 1997.
Hanauer et al., “Management of Crohn's Disease in Adults”, Amer. J. Gastroenter., vol. 92, No. 4, 1997.
Hendrickse et al., “Rifampicin-Induced Non-Responsiveness to Corticosteroid Treatment in Nephrotic Syndrome”, Brit. Med. J., p. 306, Feb. 3, 1979.
Jain et al., “Rifampicin Induced Non-Responsiveness to Steroids in Bronchial Asthma”, Indian. J. Chest. Dis. & All Sci., vol. 31, No. 4, pp. 271-274, 1989.
Jensen et al., “Competitive Reverse Transcription Polymerase Chain Reaction for Quantifying Pre-mRNA and mRNA of Major Acute Phase Proteins”, J. Immunol. Meth., vol. 215, pp. 45-48, 1998.
Jensen et al., “Review Article—Regulation of Serum Amyloid a Protein Expression During the Acute-Phase Response”, Biochem. J., vol. 334, pp. 489-503, 1998.
Jensen et al., “Evolutionary Analyses and Acute Phase Response”, J. Imunol., pp. 384-392, 1997.
Jorgensen et al., “Serum Amyloid A Transcription in Atlantic Salmon (Salmo salar L.) Hepatocytes is enhanced by Stimulation with Macrophage Factors, Recombinant Human IL-1β, IL-6 and TNFα or bacterial lipopolysaccharide”, Devel. and Compar. Immunol., vol. 24, pp. 553-563, 2000.
Kornbluth et al., “Ulcerative Colitis Practice Guidelines in Adults”, Am. J. of Gastroent., vol. 92, No. 2, 1997.
Longley et al., “Posttranscriptional Regulation of Acute Phase Serum Amyloid A2 Expression by the 5′-and 3′—Untranslated Regions of Its mRNA”, J. Immunol., pp. 4538-4545, 1999.
McCormack et al., “Generation of Soluble Recombinant Human Acute Phase Serum Amyloid A2 (A-SAA2) Protein and its Use in Development of a A-SAA Specific ELISA”, J. Immunol. Meth., vol. 198, pp. 101-110, 1996.
O'Hara et al., “Acute-Phase Serum Amyloid A Production by Rheumatoid Arthritis Synovial Tissue”, Arthritis Res. vol. 2, pp. 142-144, 2000.
O'Mahony et al., “Review Article: Management of Patients with Non-Responsive Cocliac Disease”, Aliment Pharmacol. Ther., vol. 10, pp. 671-68, 1996.
Present, “How To Do Without Steriods in Inflammatory Bowel Disease”, Inflamm. Bowel Dis., vol. 6, No. 1, Feb. 2000.
Rebuck, “Asthma: Non-Responsiveness to Conventional Therapy”, Eur. J. Respir. Dis., 69 (Suppl. 147), pp. 105-109, 1986.
Rygg et al., “In Vitro Evaluation of an Enhanced Human Serum Amyloid A (SAA2) Promoter-Regulated Soluble TNF Receptor Fusion Protein for Anti-Inflammatory Gene Therapy”, Scand. J. Immunol., vol. 53, pp. 588-595, 2001.
Spitz et al., “Response to the Antiprogestagen RU 486 (mifepristone) During Early Pregnancy and the Menstrual Cycle in Women”, J. Reprod. Fert., Suppl., vol. 37, pp. 253-260, 1989.
Steel et al., “Expression and Regulation of Constitutive and Acute Phase Serum Amyloid A mRNAs in Hepatic and Non-Hepatic Cell Lines”, Scand. J. Immunol., vol. 44, pp. 493-500, 1996.
Uhlar et al., “Wallaby Serum Amyloid A Protein: cDNA Cloning, Sequence and Evolutionary Analysis”, Scand. J. Immunol., vol. 43, pp. 271-276, 1996.
Uhlar et al., “The Kinetics and Magnitude of the Synergistic Activation of the Serum Amyloid A Promoter by IL-1 β and IL-6 is Determined by the Order of Cytokine Addition”, Scand. J. Immunol., vol. 49, pp. 399-404, 1999.
Uhlar et al., “Use of the Acute Phase Serum Amyloid A2 (SAA2) Gene Promoter in the Analysis of Pro- and Anti-Inflammatory Mediators: Differential Kinetics of SAA2 Promoter Induction by IL-1 β and TNF-α compared to IL-6”, J. Immunol. Meth., vol. 203, pp. 123-130, 1997.
Uhlar et al., “Review Article—Serum Amyloid A, the Major Vertebrate Acute-Phase Reactant”, Eur. J. Biochem., vol. 265, pp. 501-523, 1999.
Fredman Jeffrey
Morgan & Lewis & Bockius, LLP
The Trustees of the University of Pennsylvania
LandOfFree
Methods for determining steroid responsiveness does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for determining steroid responsiveness, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for determining steroid responsiveness will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3442192